FDA issued draft guidance about its plan to develop nonopioid analgesics for acute pain in an effort to spur the development of nonaddictive alternatives.FDA issued draft guidance about its plan to develop nonopioid analgesics for acute pain in an effort to spur the development of nonaddictive alternatives.

The United States Pharmacopeia (USP) has finally released its updated Chapter <797> revisions. These revisions were written over the past 22 months while USP considered appeals filed by stakeholders. The 2019 version is mostly intact in the revision, but there are some changes to beyond-use dates (BUD) for certain institutions. In addition, USP clarifies when to identify microorganisms found during various sampling activities.

HHS, along with leading clinicians, researchers, and policy experts, has established a standard clinical definition for opioid withdrawal in infants. Additionally, they have created a set of foundational principles that highlight bioethical uses for the definition that focus on identifying clinical and supportive care needs for mothers and their infants.

A new report published by CDC reveals that medical examiners are seeing a growing number of overdose deaths linked to two opioids: parafluorofentanyl and metonitazene. These drugs are frequently taken or blended with fentanyl and are said to be more powerful than fentanyl.

A review in Antimicrobial Agents and Chemotherapy found that the antibiotic development pipeline has comparatively few clinically differentiated products in late-stage clinical development, particularly against critical, multidrug-resistant pathogens.